SOURCE: Research and Markets

Research and Markets

February 17, 2016 07:31 ET

Global RNAi Therapeutics Market Report 2015-2030 -- Analysis, Technologies & Forecasts -- Key Vendors: Abbott, Biomics & Ipsen

DUBLIN, IRELAND --(Marketwired - February 17, 2016) - Research and Markets has announced the addition of the "RNAi Therapeutics Market, 2015 -- 2030" report to their offering.

The RNAi Therapeutics Market, 2015-2030 report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of RNAi therapeutics. Overall, the RNAi therapeutics market has been one of the more actively evolving markets in the past few years. However, with no marketed products till date, the market is still in its infancy.

Discovered less than two decades ago, RNAi has made its presence felt in all spheres of the pharmaceutical industry. RNAi is a natural post-transcriptional process of gene silencing involving short strands of nucleic acids. It is a regulatory process that cells utilise to silence and/or inhibit gene expression through the destruction of specific mRNA molecules.

One of the major advantages of RNAi is that it enables sequence specific knockdown of a target gene. Indications, such as age-related macular degeneration (AMD), hepatitis C and various forms of cancer,which are hard to address with the available therapies, are being considered as potential areas that can benefit from RNAi based therapeutics.

After years of research tracing back to the 1990s, a number of novel RNAi therapeutics have finally reached a point of maturity. These promising therapeutic approaches are set to be made commercially available in the near future. Innovative research, encouraging clinical trial results and growing pipelines directed towards a variety of molecular targets across different therapeutic areas have emerged as essential growth drivers of the market.

The promise has been backed by several venture capitalists and strategic investors. It is also important to highlight that partnerships amongst various stakeholders in this market have been common. Such collaborations have actively fuelled growth in the market by providing a common platform for both industry and academic research.

Several start-ups / university spin-offs have been notable flagbearers and are expected to sustain the research momentum in the coming years. The commercial success, to a certain extent, is hinged upon uncovering effective delivery routes and developing sophisticated delivery carriers for the molecules. Despite this and other associated challenges, we expect the market to make a huge leap over the coming decade.

Companies Mentioned Include:

  • 4D Molecular Therapeutics
  • AbbVie
  • Abion
  • Abott Labs
  • Advirna
  • Aegerion Pharmaceuticals
  • Aligent Technologies
  • Allele Biotechnology
  • Biomics
  • Calimmune
  • Celgene
  • Cell Signaling Technology
  • Cellecta
  • Celsion Corporation
  • Intezyne
  • Ipsen
  • Millennium Pharmaceuticals
  • miRagen Therapeutics
  • MiReven
  • MirImmune
  • Mirna Therapeutics
  • Mitsubishi Pharma Corporation
  • Monsanto
  • Merck & Co (US)
  • Nitto Denko Corporation
  • Takeda Pharmaceutical Co.
  • The Medicines Company
  • TransDerm
  • Transgene Biotek
  • TransOMIC
  • UniQure
  • YuYu Pharma

Report Structure:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Technology Platforms And Delivery Systems

6. Regional Market

7. Market Forecast

8. Key Therapeutic Indications

9. RNAi And Diagnostics

10. Vc Funding In RNAi Therapeutics

11. Partnerships In RNAi Therapeutics

12. Service Providers In RNAi Therapeutics

13. SWOT Analysis

14. Conclusion

For more information visit,

Sector: Genomics

Image Available:

Contact Information

  • Research and Markets,
    Laura Wood,
    Senior Manager.

    Fax from USA: 646-607-1907
    Fax from rest of the world: +353-1-481-1716